NGeneBio to transfer NGS tech to UAE company

It will hand over the techs of diagnostic medical devices to Dubai-based Euro Alliance, with royalties for 10 years

NGeneBio to transfer NGS tech to UAE company
Jeong Min Nam 1
2024-04-30 16:05:32 peux@hankyung.com
Bio & Pharma

South Korean medical diagnostic company NGeneBio Co. announced on Tuesday that it signed a contract with the United Arab Emirates (UAE)-based medical company Euro Alliance to transfer next-generation sequencing (NGS)-based precision diagnostic medical device manufacturing technology.

Euro Alliance is an investment and medical technology commercialization specialist company based in Switzerland and Dubai, the UAE. It conducts healthcare-related businesses in India as well.

Under the contract, NGeneBio will transfer NGS precision diagnostic products, analysis software, and production know-how to Euro Alliance in the UAE region.

The two companies will also establish a joint venture in India and the UAE for NGS business operations.

NGeneBio will receive royalties proportional to future sales over the 10 years as fees for the technology transfer. Meanwhile, Euro Alliance will handle business operations and infrastructure investments.

Write to Jeong Min Nam at peux@hankyung.com
#NGeneBio #Euro Alliance #next-generation sequencing #NGS #precision diagnostic medical device #UAE

NGeneBio gets approval for cancer diagnostic device in Thailand

NGeneBio gets approval for cancer diagnostic device in Thailand

South Korean medical diagnostic company NGeneBio Co. announced on Friday that it has received approval for the sale of its in-vitro diagnostic medical device, "SOLIDaccuTest DNA," based on next-generation sequencing (NGS) technology from the Thailand Food and Drug Administration.The product is

NGeneBio joins US gov't Cancer Moonshot project

NGeneBio joins US gov't Cancer Moonshot project

South Korean medical diagnostic company NGeneBio Co. announced on Tuesday it joins US President Joe Biden's cancer-conquering project "Cancer Moonshot."The Cancer Moonshot is a policy by the Biden Administration aiming to reduce the cancer mortality rate by over 50% in the next 25 years. An an

NGeneBio applies for US patent of early diagnosis tech of dementia

NGeneBio applies for US patent of early diagnosis tech of dementia

South Korean medical diagnostic company NGeneBio Co. announced on Thursday that it has completed the US patent application for its technology related to the diagnosis and monitoring of degenerative brain diseases based on body fluid-based tests.The technology applied for the patent this time a

NGeneBio to launch precision cancer test service in Thailand

NGeneBio to launch precision cancer test service in Thailand

South Korean medical diagnostic company NGeneBio Co. has partnered with MP Group, a large consignment testing agency in Thailand, to launch a precision cancer test service based on next-generation sequencing (NGS).On Jan. 30, NGenBio presented the need for NGS precision diagnosis and introduce

LabGenomics, NGeneBio join forces for US market

LabGenomics, NGeneBio join forces for US market

NGeneBio and LabGenomics signed an MOU to move into the US market (Yonhap) Korea's two diagnostics companies, NGeneBio Co. and LabGenomics Co., signed a memorandum of understanding (MOU) on Thursday to cooperate in the field of next-generation sequencing (NGS) services.The two companies will wo
(* comment hide *}